Contributing to the promise of Surgical Oncology
17 March 2017
Researchers and clinicians from Melanoma Institute Australia (MIA) are meeting with more than 1,700 colleagues from around the world today at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium in Seattle, USA. The theme of the meeting is “discovering the promise of what’s possible” and invites attendees to learn about the exciting possibilities for improving oncologic outcomes for patients.
The conference provides surgical oncology leaders with an opportunity to share research and network to advance the field. Four of MIA’s current or former fellows are presenting their research to colleagues at the conference, in addition to several more in attendance.
MIA's 2016 Poche Surgical Fellow, Dr Kim Isaacs, is sharing her research at the conference. Most guidelines recommend that melanoma patients have a complete lymph node dissection after they have had a positive sentinel lymph node identified; however, this doesn’t always happen. Dr Isaacs’s research investigated the factors that influence a melanoma patient’s choice to have a complete lymph node dissection or not. This research will help determine why some patients are not going ahead with this potentially life-saving surgery.
Research fellow, Trine Schoenfeldt, from Denmark is presenting her MIA research that is looking at the ideal surgical management for patients who have melanoma metastases in the sentinel nodes located near their armpit (specifically the triangular intermuscular space). How to manage patients with these metastases is considered controversial for surgeons, so having scientific evidence about the best course of treatment will ensure the best care for patients.
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.